Malignant News and Research

RSS

MicroRNA-218 especially low in medulloblastoma

Between the blueprint of the genome and the products of its expression lie microRNAs, which can boost or lower the rate at which genes become stuff. In fact, many cancers use microRNA to magnify the expression of faulty genes or shrink the expression of helpful genes that would otherwise suppress tumors. A University of Colorado Cancer Center study published in the December issue of the Journal of Biological Chemistry shows that in medulloblastoma, a malignant brain tumor of children, microRNA-218 is especially low.

14 Dec 2012

Massage could ease distress of brain cancer

Massage therapy can significantly reduce distress levels in individuals with brain tumors, indicating its potential use to improve quality of life in this population, report US researchers.

13 Dec 2012

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

13 Dec 2012

Opioids already in the body can enhance malignant tendencies of human cancer cells

A study led by University of Chicago researcher Patrick A. Singleton, Ph.D. and published in the journal Anesthesiology has shown that, even without the addition of further opioids such as morphine, opioids already in the body can enhance the malignant tendencies of human cancer cells.

13 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

Oncogene-induced senescence could play a key role in future cancer therapy

Cell aging, or cellular senescence, has an important role in the natural physiological response to tumor development. Activated oncogenes are able to induce senescence, and recent findings have suggested that oncogene-induced senescence (OIS) could play a key role in future cancer therapy.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

11 Dec 2012

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

11 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

Cocktail-treated human NK cells show promise against cancer

Fighting cancer using the body's own defense system is a promising treatment approach. Immune therapies have even become clinical routine in treating a few cancers such as malignant melanoma and prostate cancer. Natural killer cells (or NK cells) are considered to be particularly suitable weapons against cancer.

7 Dec 2012

Statins improves progression-free survival in patients with inflammatory breast cancer

Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).

6 Dec 2012

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce preliminary results from Part 1 of the Phase 1/2 clinical trial of its DNA ImmunoBody vaccine in patients with Stage III/IV malignant melanoma.

6 Dec 2012

CPRIT announces new grants to support variety of cancer-fighting research projects in Texas

The Cancer Prevention and Research Institute of Texas (CPRIT) today announced more than $85 million in funding to support 75 new scientific research projects and scientific recruits to support a variety of cancer-fighting efforts in Texas. These new awards bring the total tally of funded grants to 502, amounting to nearly $841 million since the Institute opened its doors in 2009.

6 Dec 2012

Rice bran offers promising cancer prevention properties

A recent University of Colorado Cancer Center review in the journal Advances in Nutrition shows that rice bran offers promising cancer prevention properties. Meanwhile, an ongoing clinical trial is testing the effectiveness of rice bran in preventing the recurrence of colon cancer.

6 Dec 2012

Malignant News and Research

MicroRNA-218 especially low in medulloblastoma

Massage could ease distress of brain cancer

Doctors should use different therapies when treating older and younger patients with CLL

Opioids already in the body can enhance malignant tendencies of human cancer cells

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Oncogene-induced senescence could play a key role in future cancer therapy

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

Cocktail-treated human NK cells show promise against cancer

Statins improves progression-free survival in patients with inflammatory breast cancer

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

CPRIT announces new grants to support variety of cancer-fighting research projects in Texas

Rice bran offers promising cancer prevention properties

Surprising discovery about physical properties of cancer cells

Natural killer cell response detrimental to glioblastoma virotherapy

Combination of ketogenic diet and radiation therapy effectively treats malignant gliomas

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News